Form 4: Day One Bio COO/CFO Granted Equity Awards

Day One Biopharmaceuticals' COO and CFO, Charles N. York II, was granted 188,000 stock options and 126,000 Restricted Stock Units.

Summary

• Charles N. York II, the Chief Operating Officer and Chief Financial Officer of Day One Biopharmaceuticals, Inc. (DAWN), acquired derivative securities.
• The acquisition included 188,000 stock options with an exercise price of $11.16 per share.
• These stock options will vest as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to continued service.
• The stock options have an expiration date of January 29, 2036.
• Additionally, 126,000 Restricted Stock Units (RSUs) were acquired.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15, and November 15, subject to continued service.
• RSUs do not expire but either vest or are canceled prior to the vesting date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting routine executive compensation that aligns management's interests with shareholders. It does not indicate a significant change in company fundamentals or immediate market-moving news.

Positives

• The grant of stock options and Restricted Stock Units aligns the interests of a key executive (COO and CFO) with those of shareholders, incentivizing long-term performance and retention.
• Equity compensation is a standard practice to attract and retain top talent in the biotechnology industry.

Future Outlook

The vesting schedules for both the stock options and Restricted Stock Units extend several years into the future, indicating an expectation of continued service from the COO and CFO and a long-term incentive structure tied to the company's performance.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options and Restricted Stock Units, are a common and essential component of executive compensation packages in the biotechnology and pharmaceutical sectors. These grants are designed to align executive incentives with long-term shareholder value creation and are standard practice for publicly traded companies like Day One Biopharmaceuticals.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the COO and CFO's financial interests with those of shareholders, potentially leading to more focused efforts on long-term value creation.
• Employees: The compensation structure for a key executive may influence overall compensation philosophy and morale within the company.

Next Steps

• Continued vesting of stock options and Restricted Stock Units according to their respective schedules, contingent on the reporting person's provision of service to the Issuer.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, Insider Transaction, Stock Options, Restricted Stock Units, Executive Compensation, Equity Grant, COO, CFO